Cardiovascular
Atherosclerotic Plaque
1
Pipeline Programs↗
6
Active Trials↗
6
Companies Involved↗
Atherosclerotic Plaque is an early-stage landscape with 1 program across 6 companies. The most active players are Pfizer's Upjohn has merged with Mylan to form Viatris Inc., AstraZeneca, ImmuneOnco Biopharmaceuticals (Shanghai) Inc..
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Phase 1
No programs
Phase 2
No programs
Phase 3
No programs
Approved
No programs
Analysis
Trial Status
27
clinical trials
Unknown status10 · 37%
Completed8 · 30%
Recruiting3 · 11%
Withdrawn2 · 7%
Not yet recruiting2 · 7%
Active, not recruiting1 · 4%
Other1 · 4%
Clinical Trials
Trial Activity
27 trials
The Effect of Low-dose Interleukin-2 on the Immune Landscape of Human Atherosclerotic Plaques at Single Cell Resolution.
Active, not recruiting·—·N/A·NCT05975554·30 enrolled
Evaluate the Precision of ABL-101 Perfluorocarbon and Fluorine-19 MRI for the Mapping of Atherosclerotic Plaque Composition and Inflammation in Patients Undergoing Carotid Endarterectomy
Not yet recruiting·—·Phase 2·NCT06850324·18 enrolled
Diagnosis and Therapy of Vulnerable Atherosclerotic Plaque
Completed·—·N/A·NCT00636766·300 enrolled
Beneficial Effects of Grape Seed Proanthocyanidin Extrat on Progression of Atherosclerotic Plaques in Clinical Use
Completed·—·Phase 2·NCT01707615·287 enrolled
Effects of aSPIrin Versus Aspirin Plus Low-dose RIvaroxaban on Carotid aTherosclerotic Plaque Inflammation
Completed·—·Phase 4·NCT05797376·92 enrolled
The Effect(s) of Sevelamer Carbonate (Renvela) on Atherosclerotic Plaque Inflammation Judged by FDG-PET Scan
Terminated·—·N/A·NCT01238588·24 enrolled
Page 1 of 2
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)